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Treatment with proprotein convertase subtilisin-kexin type 9
(PCSK9) inhibitors reduce low density lipoprotein cholesterol (LDL-
C) by approximately 45–60%, whether used alone or in combination
with a statin.1,2 Two large cardiovascular outcomes trials have now
reported that lowering LDL-C with a PCSK9 inhibitor when added
to treatment with a statin reduces the risk of major cardiovascular
events.3,4 We sought to compare the efficacy of PCSK9 inhibitors
and statins for reducing the risk of cardiovascular events by compar-
ing the results of the FOURIER and SPIRE trials with the results of
the Cholesterol Treatment Trialists (CTT) meta-analysis of statin
trials.5,6
In the FOURIER trial, 27 564 patients with cardiovascular disease
and LDL-C levels above 1.8 mmol/L (70 mg/dL) on statin therapy
were randomized to either 140 mg every 2 weeks (or 420 mg
monthly) of evolocumab subcutaneously or matching placebo.3 At
48 weeks, treatment with evoloculmab reduced LDL-C by 59%, from
a baseline level of 2.4 mmol/L (92 mg/dL) to 0.78 mmol/L (30 mg/dL).
Using the CTT method of imputation for missing values, this trans-
lated into a 1.4 mmol/L (53.4 mg/dL) absolute difference in LDL-C be-
tween the two treatment groups. After a median follow-up of
26 months (2.2 years), treatment with evolocumab reduced the
incidence of the composite primary cardiovascular endpoint of car-
diovascular death (CVD), myocardial infarction (MI), stroke, coron-
ary revascularization, or hospitalization for unstable angina by 15%,
from 11.3 to 9.8% (hazard ratio 0.85, 95% CI: 0.79–0.92, P< 0.001).
The key secondary endpoint of CVD, MI, or stroke was reduced by
20%, from 7.4 to 5.9% (HR 0.80, 95% CI: 0.73–0.88, P< 0.001). When
measured per mmol/L reduction in LDL-C, treatment with evolocu-
mab reduced the risk of the primary outcome by 11.0% (HR 0.89,
95% CI: 0.84–0.94) per mmol/L reduction in LDL-C, and reduced the
key secondary endpoint by 14.7% (HR 0.85, 95% CI: 0.80–0.91) per
mmol/L reduction in LDL-C. The magnitude of this effect appears to
be slightly less than the 22% reduction in risk (HR 0.78, 95% CI: 0.76–
0.80) per mmol/L reduction in LDL-C during treatment with a statin
as reported by CTT collaboration (P for difference = 1.6 10-5 for
primary outcome; P= 0.015 for secondary outcome).5,6
Similarly, in two large-scale cardiovascular outcomes trials desig-
nated as SPIRE-1 and SPIRE-2, a total of 27 438 participants with either
a history of cardiovascular disease, familial hypercholesterolaemia or
who were at high risk for cardiovascular disease were randomized to
either 150 mg every 2 weeks of bococizumab subcutaneously or
matching placebo.4 The SPIRE trials were stopped early due to high
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.rates of the development of neutralizing antidrug antibodies that re-
sulted in an attenuation of the LDL-cholesterol lowering effect of
bococizumab over time. The short duration of follow-up limits the use-
fulness of the findings in these prematurely terminated trials, but do
shed some light on the effects of this class of drug. Because the median
follow-up prior to discontinuation of the SPIRE-1 trial was only
7 months, we limit our analysis to the results of the SPIRE-2 trial which
had a median follow-up of 12 months.
Among 10 621 patients with a baseline LDL-C greater than
2.6 mmol/L (100 mg/dL) enrolled in the SPIRE-2 trial, treatment with
bococizumab reduced LDL-C by 54.6% at 14 weeks as compared to
placebo which attenuated to a 40.6% reduction at 52 weeks, resulting
in a reduction in LDL-C from a baseline level of 3.5 mmol/L
(133.9 mg/dL) to 2.1 mmol/L (79.5 mg/dL) or a 1.5 mmol/L (57.3 mg/
dL) absolute difference in LDL-C between the two treatment groups
at 1 year. After a median follow-up of 1.0 year, treatment with boco-
cizumab reduced the incidence of the primary composite outcome
of CVD, MI, stroke, or hospitalization for unstable angina requiring
urgent coronary revascularization by 21%, from 4.2 to 3.2% (HR
0.79, 95% CI: 0.65–0.97, P= 0.02), and reduced the key secondary
outcome of CVD, MI or stroke by 26%, from 3.6 to 2.7% (HR 0.74,
95% CI: 0.60–0.92, P= 0.007). When measured per mmol/L reduc-
tion in LDL-C, treatment with bococizumab reduced the risk of the
primary outcome by 14.5% (HR 0.85, 95% CI: 0.75–0.98) per mmol/L
reduction in LDL-C, and reduced the key secondary endpoint by
18.2% (HR 0.82, 95% CI: 0.71–0.94) per mmol/L reduction in LDL-C.
As observed in the FOURIER trial, the magnitude of this effect
appears to be slightly less than the 22% reduction in risk per mmol/L
reduction in LDL-C during treatment with a statin (P for differ-
ence = 0.19 for primary outcome; P= 0.52 for secondary
outcome).5,6
Indeed, when plotted on the CTT regression line, the results of
the FOURIER trial does appear to fall slightly below the regression
line describing the average expected benefit from treatment with a
statin (Figure 1A).6 However, this may not be a fair comparison. It
should be noted that the CTT regression line is based on the
observed reduction in risk per mmol/L reduction in LDL-C over an
average of 5 years of treatment with a statin. It is well recognized
from the CTT meta-analysis that statins are associated with only a
10–12% reduction in cardiovascular events per mmol/L reduction in
LDL-C during the first year of treatment, followed by a 22–24% re-
duction in risk per mmol/L reduction in LDL-C during each subse-
quent year of treatment (Table 1).5–7 Therefore, due to the short
duration of follow-up for both the FOURIER (2.2 years) and early-
terminated SPIRE-2 (1 year) trials, the relevant analysis would be to
compare the effect of PCSK9 inhibitors with the effect of statins on
the risk of cardiovascular events per mmol/L reduction in LDL-C for
the same total duration of therapy or during each year of treatment.
We can compare the effect of PCSK9 inhibitors and statins during
each year of therapy and for the same total duration of therapy by
first noting that the CTT Collaborators have indeed already reported
the effect of treatment with a statin on the risk of cardiovascular
Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular
events [cardiovascular death (CVD), myocardial infarction (MI), stroke or urgent revascularization] plotted on the overall Cholesterol Treatment
Trialists (CTT) regression line representing the observed reduction in risk per mmol/L reduction in low density lipoprotein cholesterol (LDL-C)
over an average of 5 years of treatment with a statin. (B) Effect of evolocumab and bococizumab as compared to the effect of statins by duration of
treatment (red line represents the fitted regression line for a 12% reduction in risk of major vascular events per mmol/L reduction in LDL-C after
1 year of treatment; blue line represents 17% reduction in risk of major vascular events per mmol/L reduction in LDL-C after 2 years of treatment; or-
ange line represents 20% reduction in risk of major vascular events per mmol/L reduction in LDL-C after 3 years of treatment; and grey line repre-
sents 22% reduction in risk of major vascular events per mmol/L reduction in LDL-C after 4 or more years of treatment with a statin as estimated by
the CTT collaborators). The regression line for each duration of therapy is derived by drawing a line through the estimated benefit of treatment with
a statin per mmol/L reduction in LDL-C for any duration of therapy (given in Table 1, column 7) that is forced to pass through the origin. HPS, Heart
Protection Study; 4S, Scandinavian Simvastatin Survival Study’ WOSCOPS, West of Scotland Coronary Prevention Study; CARE, Cholesterol and
Recurrent Events trial; LIPID, Long-Term Intervention with Pravastatin in Ischaemic Disease trial.
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events separately during each year of therapy (Table 1).5,6 The well-
known CTT regression line describing the effect of statins on the risk
of cardiovascular events over an average of 5 years of treatment is
derived from a meta-analysis of the separate estimates of effect dur-
ing each year of treatment. Recognizing this fact, we can calculate the
expected reduction in the risk of cardiovascular events per mmol/L
reduction in LDL-C for any duration of treatment that we choose as
described in the Table 1, and re-draw the CTT regression line to esti-
mate the effect of statins on the risk of cardiovascular events for vari-
ous durations of total treatment as shown in Figure 1B.
When analysed in this way, the PCSK9 inhibitors and statins appear
to have remarkably similar effects on the risk of cardiovascular events
for the same duration of therapy (Table 1). In the SPIRE-2 trial, 1 year
of treatment with bococizumab reduced the risk of major vascular
events (CVD, MI, stroke, or urgent revascularization) by 14.5% per
mmol/L reduction in LDL-C (HR: 0.85, 95% CI: 0.75–0.98), which is
very similar to the 12% reduction in major vascular events after 1 year
of treatment with a statin in the CTT meta-analysis. Similarly, in the
FOURIER trial, 2.2 years of treatment with evolocumab reduced the
risk of major vascular events by 16% per mmol/L reduction in LDL-C
(HR: 0.84, 95% CI: 0.80–0.88), which is nearly identical to the 17% re-
duction in major vascular events after 2 years of treatment with a sta-
tin in the CTT meta-analysis. Indeed, when the results of the
FOURIER and SPIRE-2 trials are plotted on the separate CTT regres-
sion lines recalculated for each duration of therapy, they agree very
closely with the results observed in the statin trials (Figure 1B).
Similarly, the PCSK9 inhibitors and statins also appear to have
remarkably similar effects on the risk of cardiovascular events dur-
ing each year of treatment (Figure 2). In a combined analysis of the
FOURIER and SPIRE-2 trials, treatment with either evolocumab
or bococizumab during the first year of treatment reduced the
risk of multiple different cardiovascular outcomes by 11–16%,
which is nearly identical to the 4–16% reduction in risk per mmol/
L reduction in LDL-C observed during the first year of treatment
in the statin trials. Similarly, in the FOURIER trial, treatment with
evolocumab during the second year of the trial reduced the risk of
multiple cardiovascular outcomes by 18–23% per mmol/L reduc-
tion in LDL-C, which is very similar to the 22–25% reduction in
risk for these same outcomes observed during the second year of
treatment in the statin trials (Figure 2). Together, these analyses
demonstrate that treatment with PCSK9 inhibitors and statins
have nearly identical effects on the risk of cardiovascular events
per mmol/L reduction in LDL-C when compared by total duration
of therapy and during each year of treatment.
This conclusion is strongly supported by the results of a recent
Mendelian randomization study that demonstrated that genetic vari-
ants that mimic the effect of PCSK9 inhibitors and statins have nearly
identical effects on the risk of cardiovascular disease per unit change
in LDL-C. These data suggested that inhibition of PCSK9 and HMG-
CoA reductase (the target of statins) have biologically equivalent ef-
fects on the risk of cardiovascular events per unit change in LDL-C
and therefore explicitly predicted that PCSK9 inhibitors and statins
should therefore have therapeutically equivalent effects on the risk of
cardiovascular events per unit change in LDL-C.8 As described above,
this is exactly what the FOURIER and SPIRE-2 trials showed
(Figure 2). The remarkable concordance between the naturally
randomized genetic evidence, the CTT meta-analysis of statin trials,
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Figure 2 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of variants that mimic proprotein convertase sub-
tilisin-kexin type 9 (PCSK9) inhibitors as compared to variants that mimic statins on the risk of various cardiovascular outcomes per 0.25 mmol/L
reduction in low density lipoprotein cholesterol (LDL-C). (B) Effect of PCSK9 inhibitors per mmol/L reduction in LDL-C in a meta-analysis of the
FOURIER and SPIRE-2 trials during the first year of treatment as compared with the effect of statins during the first year of treatment per mmol/L
reduction in LDL-C as reported by the Cholesterol Treatment Trialists (CTT) Collaboration. (C) Effect of PCSK9 inhibitors in the FOURIER trial per
mmol/L reduction in LDL-C during the second year of treatment as compared to the effect of statins during the second year of treatment per mmol/L
reduction in LDL-C as reported by the CTT.
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and the results of the FOURIER and SPIRE-2 trials when considered
both by total duration of therapy and during each year of treatment
clearly demonstrates that PCSK9 inhibitors and statins have equiva-
lent effects on the risk of cardiovascular events per unit change in
LDL-C. Furthermore, this concordance strongly suggests that the ef-
fect of both PCSK9 inhibitors and statins on the risk of cardiovascular
events is due entirely to the absolute achieved reduction in LDL-C
rather than to potential pleiotropic effects.
The fact that the clinical benefit of both PCSK9 inhibitors and
statins depends on the absolute magnitude of the achieved LDL-C
reduction and the total duration of treatment has important
implications for the on-going ODYSSEY OUTCOMES trial.9,10
This trial randomized 18 600 patients to biweekly injections of
alirocumab (initially 75 mg adjusted to 150 mg in a blinded fashion
to achieve an LDL-C value of between 15 and 50 mg/dL with dose
adjustment for patients with LDL-C below 15 mg/dL) or matching
placebo beginning 1 to 12 months after an index hospitalization
for acute myocardial infarction or unstable angina.10 Assuming
that the tailored-dose approach will lead to a 50% reduction in
LDL-C, treatment with alirocumab should reduce LDL-C by
approximately 1.1 mmol/L (43.2 mg/dL) from a baseline LDL-C
level of 2.2 mmol/L (86.4 mg/dL). Importantly, in the CTT meta-
analysis, treatment with a statin reduced major cardiovascular
events by 17% after 2 years of treatment and by 20% after 3 years
of treatment (Table 1). Therefore, based on an expected
median follow-up of 33 months (2.75 years), reducing LDL-C by
1.1 mmol/L with alirocumab should reduce the risk of major cardi-
ovascular events by approximately 18–22% in the ODYSSEY
OUTCOMES trial.
Finally, it is important to note that treatment with a PCSK9 inhibi-
tor was very safe even with very low absolute achieved LDL-C levels
in the FOURIER and SPIRE trials. There was no evidence of any
increased risk of neurocognitive effects or cataracts in either trial.3,4
By contrast, there was a numerically greater number of patients who
experienced new onset diabetes in the FOURIER trial (HR: 1.05, 95%
CI: 0.95–1.17, P= 0.34) and among patients with the lowest achieved
LDL-C (at least one LDL-C value < 25 mg/dL) in the SPIRE trials (HR:
1.21, 95% CI: 0.99–1.49, P= 0.07).3,4 In addition, treatment with
bococizumab was associated with a 1.74 mg/dL increase in fasting
serum glucose (95% CI: 0.56–2.92, P= 0.004) in the SPIRE trials.4
Taken together, these findings are consistent with a meta-analysis of
statin trials demonstrating that treatment with statin is associated
with a small increase in the risk of diabetes, and with Mendelian ran-
domization studies demonstrating that variants that mimic PCSK9 in-
hibitors and statins are associated with a similar increased risk of
diabetes per unit change in LDL-C.9,11 It is important to note, how-
ever, that the naturally randomized genetic evidence suggests that
only persons with impaired fasting glucose are at risk for PCSK9 or
statin induced new onset diabetes.9 Additional analysis of the
FOURIER, SPIRE, and ODESSEY trials stratified by fasting glucose
level should provide more insight into whether there is a clinically
relevant effect of PCSK9 inhibitors on the risk of new onset diabetes.
Importantly, however, it should be emphasized that both the natur-
ally randomized genetic evidence and the statin trials clearly suggest
that the beneficial effect of lowering LDL-C by inhibiting either
PCSK9 or HMG-CoA reductase far exceeds any potential risk of
new onset diabetes.9,11
In conclusion, the results of the FOURIER and SPIRE trials demon-
strate that lowering LDL-C with a PCSK9 inhibitor reduces the risk of
major cardiovascular events by the same amount as statins per mmol/L
reduction in LDL-C. The magnitude of the observed risk reduction in
the FOURIER and SPIRE trials was exactly what would have been ex-
pected based on the Cholesterol Treatment Trialists meta-analysis of
statin trials when the effect of PCSK9 inhibitors and statins are com-
pared either by total duration of treatment or by the observed effect
during each year of treatment. The remarkable concordance between
the naturally randomized genetic evidence, the results of the CTT
meta-analysis of statin trials and the results of PCSK9 inhibitor cardio-
vascular outcomes trials demonstrates that PCSK9 inhibitors and statins
reduce the risk of cardiovascular events proportional to the absolute
achieved reduction in LDL-C and the total duration of therapy.
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